{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 63 of 88', '9.1.2', 'Populations analyzed, evaluability and limitation / evaluation of bias', 'The Intention-to-Treat (ITT) population will be used for the analyses of efficacy endpoints', 'CCI', 'CCI', '9.1.3', 'Data presentation and graphics', 'For statistical analyses purpose, baseline is defined as the last measurement prior to the first', 'application of the study drug and all analyses will be summarized by visits.', 'For the summary statistics, the categorical data will be summarized by frequency and percentage', 'of subjects for each response category (N, %) and the continuous data will be summarized using', 'number of subjects, mean, median, minimum, maximum, and standard deviation.']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 64 of 88', 'Subject disposition, demographics and baseline characteristics, previous therapies, and', 'concomitant therapies will be summarized by descriptive statistics based on the ITT Population.', 'Treatment exposure and compliance data will be summarized based on the Safety Population.', 'For statistical analysis purposes, previous therapies/procedures are defined as those ending at', 'Baseline or before; and concomitant therapies/procedures are defined as those ongoing at the', 'Baseline visit or starting after the Baseline visit.', 'Treatment-emergent Adverse Events (TEAEs) are defined as AEs with onset on or after first dose', 'of study drug; or those AEs with onset prior to first dose of study drug but worsened during', 'treatment.', 'TEAEs will be tabulated in frequency tables by System Organ Class (SOC) and Preferred Term', '(PT) based on the Medical Dictionary for Regulatory Activities (MedDRA). Additional summary', 'tables will be provided for SAEs, AEs considered related to the study drug, severe AEs, AESIs,', 'and AEs leading to discontinuation. For a given AE, a subject will be counted once even if he/she', 'has experienced multiple episodes of that particular AE.', 'In addition, non TEAEs will be summarized or listed separately.', 'For local tolerability (erythema, scaling, dryness, stinging/burning), data will be summarized for', 'worst score over treatment period, the final score during treatment, as well as scores for each visit.', 'The quality of life indices, EQ-5D-5L, COMPAQ (including the anchor question), C-DLQI, and', 'DLQI will be summarized descriptively.', 'Subgroup analyses will be explored by analysis center, age (<18 years, >18 years), gender and race', 'if appropriate for efficacy endpoint, and safety endpoints (TEAEs and Local tolerability).', 'Further details will be provided in the SAP.', '9.1.3.1', 'Imputation of missing data', 'The last observation carried forward (LOCF) will be used to impute efficacy endpoints, where', 'applicable. Non-responder analysis will also be carried out for Binary endpoints.', 'Further details will be provided in the SAP.', '9.1.3.2', 'Statistical hypothesis testing and multiplicity adjustment', 'Analysis of Efficacy Endpoint', 'All efficacy and patient reported endpoints will be summarized with point estimate and 95%', 'confidence intervals.', 'Further details will be provided in SAP.']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 65 of 88', '9.2', 'Sample size determination', 'There is no formal hypothesis to be tested. An estimation approach will be performed. Point', 'estimate and 95% confidence interval will constructed. Approximately 50 subjects will be enrolled', 'to evaluate the subject reported outcomes (quality of life and satisfaction survey).', '10', 'TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE', '10.1', 'Personnel training', 'Investigators training will occur on-site during the site initiation visit. It is recommended that all', 'investigators, other evaluators, study coordinators and other applicable personnel attend the site', 'initiation visit. During these meetings/trainings,', 'CCI', 'All sites must complete photography training and submit test photos of all required light conditions', 'CCI', 'The Investigators and study coordinators are expected to attend the Investigator receive on-site', 'training during the site initiation visit prior to participating in the procedures and evaluations in', 'this study. Each site will have a training record as part of the site file and Trial Master File. An', 'Investigator Site File will be provided to each study center.', 'A study initiation visit will be conducted for each study center prior to enrollment of any subjects.', 'CRAs and other applicable personnel will be trained prior to study initiation to familiarize CRAs', 'with the disease, the Standard Operating Procedures (SOP), the protocol and other study specific', 'items. Team organization, communication and operational issues will also be discussed.', '10.2', 'Clinical monitoring', 'The conduct of the clinical trial will be closely monitored by representatives of', 'GALDERMA R&D and/or Contract Research Organization (CRO) to verify adherence to the', 'clinical trial protocol, ICH-GCP guidelines, and applicable SOPs/study procedures.']\n\n###\n\n", "completion": "END"}